Department of Pathology and Laboratory Medicine, King Hussein Cancer Center.
School of Medicine, University of Jordan, Amman, Jordan.
Appl Immunohistochem Mol Morphol. 2020 Nov/Dec;28(10):748-754. doi: 10.1097/PAI.0000000000000834.
Gastric cancer (GC) is the fifth most common cancer and the third leading cause of cancer-related mortality worldwide. Although multidisciplinary therapeutic strategies have improved treatment outcomes, the overall prognosis for patients with GC remains poor. Recently, immunotherapeutic agents targeting immunosuppressive proteins such as anti-programmed death-1 receptor and anti-programmed death ligand-1 (PD-L1) have emerged as effective treatment options for various cancers, including GC. In addition to their therapeutic role, the expression of PD-L1 has been used as a predictive biomarker for programmed death-1/PD-L1 treatment response and has been shown to have a prognostic role in certain cancers. This study aims to evaluate the expression of PD-L1 in GC samples from Jordanian patients and assess its prognostic role as well as its correlation with clinicopathologic variables. Gastrectomy samples from 96 patients diagnosed with gastric adenocarcinoma were included in the study. Immunohistochemistry assay was employed for PD-L1 testing, and the scoring was based on a combined positive score (CPS). It was found that 66.7% of the study samples were positive for PD-L1 (CPS≥1). The expression of PD-L1 was not significantly associated with any of the assessed clinicopathologic variables; however, it was found to be an independent favorable prognostic factor for overall survival (hazard ratio: 0.481; 95% confidence interval: 0.231-1.001; P=0.050).
胃癌（GC）是全球第五大常见癌症，也是癌症相关死亡的第三大主要原因。尽管多学科治疗策略改善了治疗效果，但 GC 患者的总体预后仍然较差。最近，针对免疫抑制蛋白的免疫治疗药物，如抗程序性死亡受体-1 （抗 PD-1）和抗程序性死亡配体 1 （抗 PD-L1），已成为包括 GC 在内的多种癌症的有效治疗选择。除了治疗作用外，PD-L1 的表达已被用作程序性死亡受体-1/PD-L1 治疗反应的预测生物标志物，并在某些癌症中具有预后作用。本研究旨在评估来自约旦患者的 GC 样本中 PD-L1 的表达，并评估其预后作用及其与临床病理变量的相关性。本研究纳入了 96 例经诊断为胃腺癌的胃切除术样本。采用免疫组织化学法检测 PD-L1，评分基于综合阳性评分（CPS）。结果发现，研究样本中有 66.7%为 PD-L1 阳性（CPS≥1）。PD-L1 的表达与评估的任何临床病理变量均无显著相关性；然而，它被发现是总生存的独立有利预后因素（风险比：0.481；95%置信区间：0.231-1.001；P=0.050）。
